{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:50:41Z","timestamp":1791085841977,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1002\/jps.23686","type":"journal-article","created":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T00:20:48Z","timestamp":1375748448000},"page":"3748-3761","source":"Crossref","is-referenced-by-count":73,"title":["Development and Evaluation of Paclitaxel Nanoparticles Using a Quality-by-Design Approach"],"prefix":"10.1016","volume":"102","author":[{"given":"Firat","family":"Yerlikaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysegul","family":"Ozgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Vural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olgun","family":"Guven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ergun","family":"Karaagaoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilmaz","family":"Capan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/jps.23686_bb0010","series-title":"Guidance for industry: PAT\u2014A framework for innovative pharmaceutical development, manufacturing, and quality assuranc","author":"US FDA","year":"2004"},{"key":"10.1002\/jps.23686_bb0015","series-title":"Q8(R2): Pharmaceutical Development","author":"ICH","year":"2009"},{"key":"10.1002\/jps.23686_bb0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpba.2012.01.002","article-title":"Application of quality by design elements for the development and optimization of an analytical method for protamine sulfat","volume":"62","author":"Awotwe-Otoo","year":"2012","journal-title":"J Pharm Biomed Ana"},{"issue":"6","key":"10.1002\/jps.23686_bb0025","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3109\/10837450.2011.611138","article-title":"Quality by design in formulation and process development for a freeze-dried, small molecule parenteral product: A case stud","volume":"16","author":"Mockus","year":"2011","journal-title":"Pharm Dev Techno"},{"issue":"1\u20132","key":"10.1002\/jps.23686_bb0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijpharm.2007.04.009","article-title":"Quality by design: Characterization of self-nano-emulsified drug delivery systems (SNEDDs) using ultrasonic resonator technolog","volume":"341","author":"Shah","year":"2007","journal-title":"Int J Phar"},{"issue":"1\u20132","key":"10.1002\/jps.23686_bb0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpharm.2009.05.006","article-title":"Quality by design approach to understand the process of nanosuspension preparatio","volume":"377","author":"Verma","year":"2009","journal-title":"Int J Phar"},{"issue":"8","key":"10.1002\/jps.23686_bb0040","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1002\/jps.21646","article-title":"Quality-by-design (QbD): An integrated approach for evaluation of powder blending process kinetics and determination of powder blending end-poin","volume":"98","author":"Wu","year":"2009","journal-title":"J Pharm Sc"},{"issue":"3","key":"10.1002\/jps.23686_bb0045","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/jps.21923","article-title":"Quality-by-design (QbD): An integrated process analytical technology (PAT) approach for real-time monitoring and mapping the state of a pharmaceutical coprecipitation proces","volume":"99","author":"Wu","year":"2010","journal-title":"J Pharm Sc"},{"issue":"1\u20132","key":"10.1002\/jps.23686_bb0050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijpharm.2009.01.002","article-title":"Quality-by-design (QbD): An integrated multivariate approach for the component quantification in powder blend","volume":"372","author":"Wu","year":"2009","journal-title":"Int J Phar"},{"issue":"10","key":"10.1002\/jps.23686_bb0055","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1002\/jps.21320","article-title":"Quality-by-design (QbD): Effects of testing parameters and formulation variables on the segregation tendency of pharmaceutical powder measured by the ASTM D 6940\u201304 segregation teste","volume":"97","author":"Xie","year":"2008","journal-title":"J Pharm Sc"},{"issue":"1\u20132","key":"10.1002\/jps.23686_bb0060","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijpharm.2012.06.002","article-title":"Application of quality by design to formulation and processing of protein liposome","volume":"434","author":"Xu","year":"2012","journal-title":"Int J Phar"},{"issue":"2","key":"10.1002\/jps.23686_bb0065","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijpharm.2011.11.036","article-title":"A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scal","volume":"423","author":"Xu","year":"2012","journal-title":"Int J Phar"},{"issue":"9","key":"10.1002\/jps.23686_bb0070","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/jps.20824","article-title":"Quality by design: Understanding the product variability of a self-nanoemulsified drug delivery system of cyclosporine","volume":"96","author":"Zidan","year":"2007","journal-title":"J Pharm Sc"},{"issue":"1","key":"10.1002\/jps.23686_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10601330701220520","article-title":"Design of experiments: Concept and applications of Plackett\u2013Burman desig","volume":"24","author":"Vanaja","year":"2007","journal-title":"Clin Res Regul Af"},{"issue":"1\u20132","key":"10.1002\/jps.23686_bb0080","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2012.08.033","article-title":"Quality by design: Impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibod","volume":"438","author":"Awotwe-Otoo","year":"2012","journal-title":"Int J Phar"},{"issue":"4","key":"10.1002\/jps.23686_bb0085","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/00401706.1960.10489912","article-title":"Some new three level designs for the study of quantitative variable","volume":"2","author":"Box","year":"1960","journal-title":"Technometric"},{"issue":"2","key":"10.1002\/jps.23686_bb0090","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0378-5173(99)00324-5","article-title":"Captopril gastrointestinal therapeutic system coated with cellulose acetate pseudolatex: Evaluation of main effects of several formulation variable","volume":"193","author":"Khan","year":"2000","journal-title":"Int J Phar"},{"issue":"4","key":"10.1002\/jps.23686_bb0095","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/biomet\/33.4.305","article-title":"The design of optimum multifactorial experiment","volume":"33","author":"Plackett","year":"1946","journal-title":"Biometrik"},{"issue":"1\u20132","key":"10.1002\/jps.23686_bb0100","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijpharm.2009.12.040","article-title":"Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett\u2013Burman desig","volume":"389","author":"Rahman","year":"2010","journal-title":"Int J Phar"},{"issue":"1\u20132","key":"10.1002\/jps.23686_bb0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijpharm.2006.09.060","article-title":"Quality by design: Understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box\u2013Behnken design and desirability functio","volume":"332","author":"Zidan","year":"2007","journal-title":"Int J Phar"},{"issue":"1\u20132","key":"10.1002\/jps.23686_bb0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijpharm.2011.05.014","article-title":"Characterization, pharmacokinetics and disposition of novel nanoscale preparations of paclitaxe","volume":"414","author":"Wang","year":"2011","journal-title":"Int J Phar"},{"issue":"1","key":"10.1002\/jps.23686_bb0115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejpb.2010.11.008","article-title":"High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: Quality by design optimization and characterizatio","volume":"77","author":"Cun","year":"2011","journal-title":"Eur J Pharm Biophar"},{"issue":"7","key":"10.1002\/jps.23686_bb0120","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/jps.21612","article-title":"Preparation and characterization of negatively charged poly(lactic-co-glycolic acid) microsphere","volume":"98","author":"Xu","year":"2009","journal-title":"J Pharm Sc"},{"issue":"11","key":"10.1002\/jps.23686_bb0125","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s11095-009-9965-4","article-title":"PLGA nanoparticles stabilized with cationic surfactant: Safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in ra","volume":"26","author":"Bhardwaj","year":"2009","journal-title":"Pharm Re"},{"issue":"11","key":"10.1002\/jps.23686_bb0130","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3109\/03639045.2010.487263","article-title":"Application of rotatable central composite design in the preparation and optimization of poly(lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxe","volume":"36","author":"Kollipara","year":"2010","journal-title":"Drug Dev Ind Phar"},{"issue":"6","key":"10.1002\/jps.23686_bb0135","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1023\/A:1016419303727","article-title":"The preparation and evaluation of drug-containing poly(dl-lactide) microspheres formed by the solvent evaporation metho","volume":"4","author":"Bodmeier","year":"1987","journal-title":"Pharm Re"},{"issue":"1\u20132","key":"10.1002\/jps.23686_bb0140","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijpharm.2011.07.012","article-title":"A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessmen","volume":"419","author":"Xu","year":"2011","journal-title":"Int J Phar"},{"issue":"1\u20132","key":"10.1002\/jps.23686_bb0145","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijpharm.2007.02.011","article-title":"Enhanced solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluatio","volume":"338","author":"Yang","year":"2007","journal-title":"Int J Phar"},{"issue":"9","key":"10.1002\/jps.23686_bb0150","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/CAD.0b013e328330c811","article-title":"In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cell","volume":"20","author":"Gao","year":"2009","journal-title":"Anticancer Dru"},{"issue":"4","key":"10.1002\/jps.23686_bb0155","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/10717544.2012.674163","article-title":"PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cell","volume":"19","author":"Sarisozen","year":"2012","journal-title":"Drug Deli"},{"issue":"2","key":"10.1002\/jps.23686_bb0160","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.colsurfb.2010.07.050","article-title":"Preparation and characterization of biodegradable paclitaxel loaded alginate microparticles for pulmonary deliver","volume":"81","author":"Alipour","year":"2010","journal-title":"Colloids Surf B Biointerface"},{"issue":"12","key":"10.1002\/jps.23686_bb0165","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.2042-7158.1972.tb08930.x","article-title":"Linearization of dissolution rate curves by the Weibull distributio","volume":"24","author":"Langenbucher","year":"1972","journal-title":"J Pharm Pharmaco"},{"issue":"1","key":"10.1002\/jps.23686_bb0170","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1081\/DDC-100100328","article-title":"Biodegradable progesterone microsphere delivery system for osteoporosis therap","volume":"26","author":"Yang","year":"2000","journal-title":"Drug Dev Ind Phar"},{"issue":"1\u20132","key":"10.1002\/jps.23686_bb0175","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijpharm.2007.04.022","article-title":"The characterization of paclitaxel-loaded microspheres manufactured from blends of poly(lactic-co-glycolic acid) (PLGA) and low molecular weight diblock copolymer","volume":"342","author":"Jackson","year":"2007","journal-title":"Int J Phar"},{"issue":"2","key":"10.1002\/jps.23686_bb0180","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijpharm.2008.04.042","article-title":"Principles of encapsulating hydrophobic drugs in PLA\/PLGA microparticle","volume":"364","author":"Wischke","year":"2008","journal-title":"Int J Phar"},{"issue":"2","key":"10.1002\/jps.23686_bb0185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","article-title":"Modeling and comparison of dissolution profile","volume":"13","author":"Costa","year":"2001","journal-title":"Eur J Pharm Sc"},{"issue":"1","key":"10.1002\/jps.23686_bb0190","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0168-3659(00)00364-3","article-title":"Effects of emulsifiers on the controlled release of paclitaxel (Taxol (R)) from nanospheres of biodegradable polymer","volume":"71","author":"Feng","year":"2001","journal-title":"J Control Releas"},{"key":"10.1002\/jps.23686_bb0195","series-title":"Q3C(R4) Impurities: Guideline for residual solvent","author":"ICH","year":"2009"},{"issue":"9","key":"10.1002\/jps.23686_bb0200","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/0008-5472.CAN-08-2747","article-title":"Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting AT","volume":"69","author":"Dong","year":"2009","journal-title":"Cancer Re"},{"key":"10.1002\/jps.23686_bb0205","first-page":"2805","article-title":"pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherap","volume":"7","author":"Shin","year":"2012","journal-title":"Int J Nanomedicin"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915308935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915308935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T04:31:54Z","timestamp":1539491514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915308935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0022354915308935"],"URL":"https:\/\/doi.org\/10.1002\/jps.23686","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}